Clinical trial
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
NCT02286947 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2014
- Completion date
- March 23, 2018
- Enrollment
- 24 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.